Outcome of the Board Meeting held on 08th November 2025 for approval of unaudited Financial Results for the Quarter and Half year ended on 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenlabs Ethica Ltd's board approved unaudited financial results for Q2 FY26 and H1 FY26 (ended 30 Sept 2025). Revenue from operations for Q2 stood at ₹1,243.34 lakhs, down from ₹1,335.15 lakhs in Q2 FY25, a decline of about 7%. For H1 FY26, revenue came in at ₹2,391.06 lakhs versus ₹2,571.41 lakhs in H1 FY25. Profit after tax for H1 FY26 was ₹7.09 lakhs versus ₹9.35 lakhs last year, with EPS at ₹0.11 (vs ₹0.14). The company operates as a single-segment pharma formulation trader. Statutory auditors N Kumar Chhabra and Co. issued an unmodified limited review opinion. Operating cash flow remained positive at ₹346.36 lakhs, though lower than ₹431.35 lakhs in H1 FY25.
Results are weak with revenue and profits both declining year-on-year on a lower base, and margins slightly compressed, which is mildly negative for the stock. However, debt levels have come down, cash balances improved, and the auditor gave a clean opinion, limiting downside risk.